IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

IMV announced its executive management team's participation in the H.C. Wainwright Global Life Sciences Conference, taking place virtually on March 9-10, 2021. The presentation is scheduled for March 9 at 7:00 AM ET and will be available for 30 days on IMV’s website. The company is pioneering cancer immunotherapies and vaccines, with a focus on its lead candidate, DPX-Survivac, which targets survivin. IMV highlights potential FDA accelerated approval and the ongoing clinical studies for its therapies.

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that IMV’s executive management team will be participating at the H.C. Wainwright Global Life Sciences Conference which will be held virtually on March 9-10.

H.C. Wainwright Global Life Sciences Conference

Presentation availability time: Tuesday, March 9, 2021 at 7:00 AM Eastern Time

A link to this presentation will be available under “Events, Webcasts and Presentations” in the investors section of IMV’s website at the above-mentioned time and for approximately 30 days thereafter.

IMV Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the FDA potentially granting accelerated regulatory approval of DPX-Survivac and the timing of expected results from other DPX-Survivac’s studies with other tumor types. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Corporation, including access to capital, the successful design and completion of clinical trials and the receipt and timely receipt of all regulatory approvals. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion of clinical trials and studies, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly filings and annual information form Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer immunotherapies and vaccines against infectious diseases based on the Company’s proprietary drug delivery platform, DPX. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Visit www.imv-inc.com and connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005049/en/

FAQ

When is IMV's presentation at the H.C. Wainwright Global Life Sciences Conference?

IMV's presentation is scheduled for March 9, 2021, at 7:00 AM Eastern Time.

Where can I find the IMV presentation from the H.C. Wainwright Conference?

The presentation will be available on IMV's website under 'Events, Webcasts and Presentations' for approximately 30 days after March 9, 2021.

What is the focus of IMV's lead candidate DPX-Survivac?

DPX-Survivac is a T cell-activating immunotherapy targeting the survivin protein, currently assessed in advanced ovarian cancer.

What is the significance of the H.C. Wainwright Global Life Sciences Conference for IMV?

The conference provides IMV an opportunity to present its innovative immunotherapy advancements to investors and stakeholders in the life sciences.

What type of company is IMV?

IMV is a clinical-stage biopharmaceutical company focused on cancer immunotherapy and vaccines for infectious diseases.